News Image

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: Mar 31, 2025

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –

– Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 –

Read more at globenewswire.com

CABALETTA BIO INC

NASDAQ:CABA (5/30/2025, 8:00:01 PM)

After market: 1.8699 0 (-0.01%)

1.87

-0.04 (-2.09%)



Find more stocks in the Stock Screener

CABA Latest News and Analysis

ChartMill News Image16 days ago - ChartmillTop movers in Friday's pre-market session

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Mentions: GTI GLOB EVLV AYTU ...

ChartMill News Image17 days ago - ChartmillThese stocks are gapping in today's session

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Mentions: BOOT GTI FL TE ...

Follow ChartMill for more